| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |